Unlocking Tilray’s Potential: TLRY Stock Soars with German Trading License for Aphria RX
Tilray (NASDAQ:TLRY) investors are buzzing as the cannabis company secures a trading license in Germany for its Aphria RX subsidiary. This milestone allows Aphria RX to distribute medical cannabis products to pharmacies, hospitals, and wholesalers in Germany, building on Tilray’s existing cultivation license in the country.
Denise Faltischek, Chief Strategy Officer at Tilray, emphasized the significance of this achievement, stating, “This milestone of Aphria RX obtaining both its new cultivation license as well as its trading license further expands Tilray’s leadership in medical cannabis research, cultivation, production and distribution in Germany.”
Despite this positive news, TLRY stock is experiencing minimal trading activity today, with only 12 million shares exchanged compared to its daily average of 21 million shares. However, the stock is showing a slight gain on Monday afternoon.
Stay tuned for more updates on TLRY stock and other market movers like Palantir Technologies (NYSE:PLTR), AMC Entertainment (NYSE:AMC), and Tivic Health Systems (NASDAQ:TIVC). For the latest stock market news, click on the links below!
In conclusion, Tilray’s German trading license for Aphria RX is a significant milestone that solidifies its position in the medical cannabis market. Investors should keep an eye on TLRY stock as it continues to navigate the evolving landscape of the cannabis industry.